Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what evidence was considered before the decision not to make Kalydeco available to children under two with cystic fibrosis; and whether there are plans to reconsider this decision.

NHS England is not able to consider making ivacaftor (Kalydeco) available to children under two with cystic fibrosis as it is not licensed for that age group.